CapsoVision (NASDAQ:CV) Now Covered by Roth Capital

Key Points

• Roth Capital initiated coverage of CapsoVision with a “buy” rating and a $9.00 price target, implying 45.63% upside from the previous close.
• Analyst sentiment remains mixed: MarketBeat reports a consensus “hold” rating and an average target price of $9.50, alongside buy, hold and sell ratings from other firms.
• CapsoVision reported a quarterly loss of $0.15 per share on $3.64 million in revenue, while insiders purchased more than 156,000 shares worth approximately $1.01 million over the past quarter.

Research analysts at Roth Capital initiated coverage on shares of CapsoVision (NASDAQ:CV - Get Free Report) in a research note issued on Friday, MarketBeat Ratings reports. The brokerage set a "buy" rating and a $9.00 price target on the stock. Roth Capital's price target suggests a potential upside of 45.63% from the company's previous close.

CV has been the topic of a number of other reports. Weiss Ratings reissued a "sell (d-)" rating on shares of CapsoVision in a research note on Monday, June 29th. Benchmark reaffirmed a "speculative buy" rating on shares of CapsoVision in a report on Friday, August 14th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $9.50.

CapsoVision Stock Performance

Shares of CV stock traded up $0.12 during trading on Friday, hitting $6.18. The company had a trading volume of 6,750 shares, compared to its average volume of 246,728. The firm has a market capitalization of $309.31 million and a P/E ratio of -13.15. CapsoVision has a one year low of $3.43 and a one year high of $15.37. The stock's 50-day moving average price is $6.59 and its 200 day moving average price is $6.39.

CapsoVision (NASDAQ:CV - Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($0.15) earnings per share for the quarter. CapsoVision had a negative net margin of 214.74% and a negative return on equity of 177.85%. The company had revenue of $3.64 million for the quarter.

Insider Buying and Selling at CapsoVision

In related news, major shareholder Eliyahou Et Al Harari purchased 61,068 shares of the stock in a transaction dated Friday, July 17th. The stock was bought at an average cost of $6.73 per share, for a total transaction of $410,987.64. Following the completion of the acquisition, the insider owned 3,343,119 shares of the company's stock, valued at approximately $22,499,190.87. This represents a 1.86% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have acquired a total of 156,218 shares of company stock worth $1,007,902 over the last quarter. Insiders own 2.30% of the company's stock.

Hedge Funds Weigh In On CapsoVision

A number of institutional investors and hedge funds have recently bought and sold shares of the company. State Street Corp boosted its stake in shares of CapsoVision by 340.7% during the fourth quarter. State Street Corp now owns 85,929 shares of the company's stock valued at $919,000 after purchasing an additional 66,429 shares in the last quarter. Millennium Management LLC bought a new position in CapsoVision in the 4th quarter valued at approximately $163,000. Virtu Financial LLC acquired a new stake in CapsoVision during the 4th quarter worth approximately $128,000. Citadel Advisors LLC acquired a new stake in CapsoVision during the 3rd quarter worth approximately $115,000. Finally, Wells Fargo & Company MN grew its holdings in CapsoVision by 66.4% during the 4th quarter. Wells Fargo & Company MN now owns 6,287 shares of the company's stock worth $67,000 after acquiring an additional 2,508 shares during the last quarter.

CapsoVision Company Profile

CapsoVision, Inc NASDAQ: CV is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source